Soquelitinib (CPI-818)

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biotech focused on developing precisely-targeted small molecule therapies for cancer and immune diseases, anchored by its proprietary ITK inhibition platform. Its lead asset, soquelitinib, is a first-in-class oral ITK inhibitor designed to modulate T cell differentiation, with multiple Phase 1/1b trials underway in T cell lymphomas and solid tumors. The company's strategy emphasizes establishing monotherapy proof-of-concept to de-risk development, guided by a leadership team with seminal experience in bringing blockbuster oncology drugs like Rituxan and Imbruvica to market.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biotech focused on developing precisely-targeted small molecule therapies for cancer and immune diseases, anchored by its proprietary ITK inhibition platform. Its lead asset, soquelitinib, is a first-in-class oral ITK inhibitor designed to modulate T cell differentiation, with multiple Phase 1/1b trials underway in T cell lymphomas and solid tumors. The company's strategy emphasizes establishing monotherapy proof-of-concept to de-risk development, guided by a leadership team with seminal experience in bringing blockbuster oncology drugs like Rituxan and Imbruvica to market.

Therapeutic Areas